You just read:

Heron Announces FDA Approval of Supplemental New Drug Application to Expand CINVANTI® Label for Single-Dose Regimen for Patients Receiving Moderately Emetogenic Chemotherapy (MEC)

News provided by

Heron Therapeutics, Inc.

Oct 22, 2019, 08:30 ET